Pharmaceutical Industry Leaders Emphasize Importance of Collaboration, Patient Empowerment, and Global Perspective in Healthcare

Pharmaceutical industry leaders, such as Dr. Armin Kessler, chief operating officer and member of the board for F. Hoffmann-La Roche, are advocating for a stronger role in healthcare discussions and policy reforms. Dr. Kessler emphasizes the need for industry to participate in a broad range of healthcare discussions, including a 12-nation study on the financing and delivery of healthcare, sponsored by Pharmaceutical Partners for Better Healthcare (PPBH). The study aims to provide insights into healthcare systems and the role of industry in addressing unmet medical needs.

Key Takeaways:

• The pharmaceutical industry is undergoing significant changes, with a focus on reducing inefficiencies and streamlining internal business processes.
• Industry leaders, such as Dr. Kessler, are actively participating in healthcare discussions, including a 12-nation study on healthcare financing and delivery.
• The PPBH, a group of 40 research-based pharmaceutical companies, is sponsoring the study and co-sponsoring a workshop on healthcare reforms in Europe.
• The industry's mission in healthcare is to discover new medicines for society's unmet medical needs, including cancer, Alzheimer's, osteoporosis, multiple sclerosis, and others.
• At least 10 million patients worldwide suffer from Alzheimer's alone, highlighting the need for effective treatments and patient empowerment.
• Patients are being treated as true partners in healthcare, with industry leaders recognizing their importance in shaping healthcare systems.
• The industry must communicate better about the role and value of medicines and share its global experience and perspective on trends and challenges facing healthcare systems.

Statistics:

• At least 10 million patients worldwide suffer from Alzheimer's.
• The pharmaceutical industry is involved in a 12-nation study on healthcare financing and delivery.
• 45 leaders from EU, Member States, academia, and industry participated in a recent workshop in Europe on healthcare reforms.
• PPBH is sponsored by almost 40 research-based pharmaceutical companies from the US, Europe, and Japan.
• Industry leaders are planning to publish additional studies on cost-sharing trends and insurance risk-adjustment later this year.

Sources:

• Pharmaceutical Partners for Better Healthcare (PPBH)
• F. Hoffmann-La Roche
• FT World Pharmaceuticals Conference
• London School of Economics
• EU institutions